Steven M Devine

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
    Steven M Devine
    Steven M Devine and William Blum, Ohio State University, Columbus, OH Kouros Owzar, Flora Mulkey, Vera Hars, and Alexander B Sibley, Alliance Statistics and Data Center, Duke University, Durham Thomas C Shea, University of North Carolina, Chapel Hill, NC Richard M Stone, Robert J Soiffer, and Edwin P Alyea, Dana Farber Cancer Institute Yi Bin Chen, Massachusetts General Hospital, Boston, MA Jack W Hsu, University of Florida, Gainesville, FL Richard E Champlin, MD Anderson Cancer Research Center, Houston, TX Ravi Vij, Washington University, St Louis, MO James Slack, Mayo Clinic, Scottsdale, AZ Richard A Larson, University of Chicago, Chicago, IL Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY Shelly Carter, The EMMES Corporation, Bethesda, MD Mary M Horowitz, Medical College of Wisconsin, Milwaukee, Finland
    J Clin Oncol 33:4167-75. 2015
  2. pmc Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot
    Steven M Devine
    Medicine Department of Ohio State University, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 17:1343-51. 2011
  3. doi request reprint Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
  4. pmc Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
  5. pmc Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
  6. pmc Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303
    Carolyn A Keever-Taylor
    Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 18:690-7. 2012
  7. doi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
  8. pmc Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 51:243-51. 2010
  9. pmc Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
    Neil C Dunavin
    Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Leuk Lymphoma 54:1658-64. 2013
  10. ncbi request reprint A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
    Thomas Fong
    Division of Oncology, Section of Leukemia and Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 13:1201-6. 2007

Detail Information

Publications49

  1. pmc Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
    Steven M Devine
    Steven M Devine and William Blum, Ohio State University, Columbus, OH Kouros Owzar, Flora Mulkey, Vera Hars, and Alexander B Sibley, Alliance Statistics and Data Center, Duke University, Durham Thomas C Shea, University of North Carolina, Chapel Hill, NC Richard M Stone, Robert J Soiffer, and Edwin P Alyea, Dana Farber Cancer Institute Yi Bin Chen, Massachusetts General Hospital, Boston, MA Jack W Hsu, University of Florida, Gainesville, FL Richard E Champlin, MD Anderson Cancer Research Center, Houston, TX Ravi Vij, Washington University, St Louis, MO James Slack, Mayo Clinic, Scottsdale, AZ Richard A Larson, University of Chicago, Chicago, IL Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY Shelly Carter, The EMMES Corporation, Bethesda, MD Mary M Horowitz, Medical College of Wisconsin, Milwaukee, Finland
    J Clin Oncol 33:4167-75. 2015
    ..We sought to prospectively determine the value of HSCT for older patients with AML in first complete remission...
  2. pmc Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot
    Steven M Devine
    Medicine Department of Ohio State University, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 17:1343-51. 2011
    ..HCT after myeloablative chemoradiotherapy can be performed in a multicenter setting using a uniform method of TCD, resulting in a low risk of extensive chronic GVHD and relapse for patients with AML in CR1...
  3. doi request reprint Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
    ..This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov...
  4. pmc Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
    ....
  5. pmc Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
    ..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
  6. pmc Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303
    Carolyn A Keever-Taylor
    Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 18:690-7. 2012
    ..Products processed at multiple centers using the CliniMACS System for CD34 enrichment were comparably and uniformly highly enriched for CD34(+) cells, with good CD34(+) cell recovery and very low CD3(+) T cell content...
  7. doi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
    ..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates...
  8. pmc Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 51:243-51. 2010
    ..Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies...
  9. pmc Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
    Neil C Dunavin
    Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Leuk Lymphoma 54:1658-64. 2013
    ..037). No superiority of one agent was seen. In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies...
  10. ncbi request reprint A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
    Thomas Fong
    Division of Oncology, Section of Leukemia and Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 13:1201-6. 2007
    ..15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival...
  11. ncbi request reprint Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
    Christopher L Hallemeier
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 12:749-57. 2006
    ..In patients with MDS, this is an effective RIC regimen for allogeneic transplantation that can be used as an alternative to other RIC or conventional conditioning regimens...
  12. doi request reprint High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Eur J Haematol 81:425-31. 2008
    ..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively...
  13. pmc Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 150:189-95. 2010
    ..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL...
  14. pmc Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:349-56. 2009
    ..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted...
  15. pmc Outcome of transplantation for myelofibrosis
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Blood Marrow Transplant 16:358-67. 2010
    ..In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients...
  16. pmc Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  17. pmc Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor
    David A Hess
    Department of Internal Medicine, Division of Oncology, Hematopoietic Development and Malignancy Group, Washington University School of Medicine, 4940 Parkview Place, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 13:398-411. 2007
    ..Thus, AMD3100 mobilized peripheral blood represents a rapidly obtained, highly repopulating source of hematopoietic progenitors for clinical transplantation...
  18. doi request reprint Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma
    Tanya M Wildes
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:840-6. 2008
    ..Comorbidities significantly influenced TRM and OS in this retrospective cohort. Future study should focus on improving tolerability of conditioning and careful prospective evaluation of comorbidities and their association with outcomes...
  19. pmc Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma
    Jarrod T Bruce
    Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Clin Lymphoma Myeloma Leuk 12:325-9. 2012
    ..It also suggests that routine pulmonary function testing may be required in patients receiving these medications until larger studies can be performed to confirm this observation...
  20. pmc Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012
    ..This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials...
  21. pmc Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
    Yvonne A Efebera
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio Electronic address
    Biol Blood Marrow Transplant 22:71-9. 2016
    ..These results did not differ from our historical control subjects (n = 96). Although safe and tolerable, the addition of atorvastatin did not appear to provide any benefit to standard GVHD prophylaxis alone. ..
  22. pmc Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
    Jonathon B Cohen
    Division of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio
    Cancer 120:1677-85. 2014
    ..In this study, the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University...
  23. doi request reprint Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
    Philippe Armand
    Philippe Armand and Edie Weller, Dana Farber Cancer Institute David E Avigan, Beth Israel Deaconess Medical Center Yi Bin Chen, Massachusetts General Hospital, Boston, MA Arnon Nagler, Chaim Sheba Medical Center, Tel Hashomer Reuven Or, Hadassah Medical Center, Jerusalem Rinat Rotem Yehudar, CureTech, Yavne, Israel Steven M Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus Hillard M Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH Mark S Kaminski, University of Michigan, Ann Arbor, MI H Kent Holland, Northside Hospital Edmund K Waller, Winship Cancer Institute, Emory University, Atlanta, GA Jane N Winter and Leo I Gordon, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine Stephanie A Gregory, Rush Medical Center, Chicago, IL James R Mason, Scripps Clinic Edward D Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego John M Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA Joseph W Fay, Baylor Research Institute, Department of Internal Medicine
    J Clin Oncol 31:4199-206. 2013
    ..The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable for breaking immune tolerance through PD-1 blockade...
  24. pmc Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant
    Galena Salem
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 56:1058-65. 2015
    ..5 mg/kg ATG. Given the increasing number of RIC HSCTs performed worldwide, the correct dose and preparation of ATG should be defined by prospective randomized trials. ..
  25. pmc Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease
    Ming J Poi
    Department of Pharmacy, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH, USA
    Clin Pharmacokinet 52:705-12. 2013
    ..This phase II study (NCT00201786) was conducted to assess pentostatin efficacy and infectious complications seen from our previous phase I study in steroid-refractory acute GVHD (aGVHD)...
  26. ncbi request reprint Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Ravi Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 101:2067-9. 2003
    ..This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population...
  27. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
    ..A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered...
  28. pmc Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
    ..Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment...
  29. ncbi request reprint Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor
    Beth Christian
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 28:e629-32. 2010
  30. pmc Tocilizumab for steroid refractory acute graft-versus-host disease
    Julianna V F Roddy
    a Department of Pharmacy, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
    Leuk Lymphoma 57:81-5. 2016
    ..Our limited experience demonstrated an overall response rate of 44% (CR + PR); however, this response was not durable. Further studies are needed to determine the optimal time for tocilizumab initiation. ..
  31. ncbi request reprint Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma
    Steven M Devine
    Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 22:1095-102. 2004
    ..We performed a phase I study assessing the safety and clinical effects of AMD3100 in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)...
  32. ncbi request reprint Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients
    Hillard M Lazarus
    Department of Medicine, The University Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
    Biol Blood Marrow Transplant 11:389-98. 2005
    ..The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials...
  33. pmc Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
    ..Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia...
  34. doi request reprint Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease
    Sumithira Vasu
    Division of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Biol Blood Marrow Transplant 22:658-68. 2016
    ..NKT cells and early activated T cells are associated with lower relapse risk in AML and MDS patients. These findings may have implications in therapeutic targeting of select populations in the allograft to minimize incidence of GVHD. ..
  35. pmc Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
    ..The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections...
  36. pmc Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia
    Samantha M Jaglowski
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    Br J Haematol 159:82-7. 2012
    ..In patients with high-risk interphase cytogenetics, CK remained predictive of worse OS (P = 0·02) and EFS (P = 0·009). These findings support further evaluation of metaphase karyotype in transplant risk assessment...
  37. doi request reprint Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study
    Thomas Bechtel
    Stem Cell Transplant, Arthur G James Cancer Hospital, The Ohio State University, Columbus, OH, USA
    Support Care Cancer 22:2911-6. 2014
    ..The aim of this study is to evaluate the efficacy of aprepitant as part of the antiemetic regimen for high-dose melphalan conditioning in multiple myeloma patients...
  38. pmc FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome
    Shun He
    Division of Hematology, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Biol Blood Marrow Transplant 20:309-13. 2014
    ..Collectively, FP represents a promising novel and potent mobilization regimen with potential clinical application in both the autologous and allogeneic transplantation settings...
  39. pmc MicroRNAs activate natural killer cells through Toll-like receptor signaling
    Shun He
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:4663-71. 2013
    ..This may be important in the normal host defense against infection and/or malignant transformation...
  40. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  41. ncbi request reprint Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
    Br J Haematol 135:642-50. 2006
    ..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed...
  42. ncbi request reprint Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system
    Erik R Dubberke
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    Infect Control Hosp Epidemiol 28:208-11. 2007
    ..Patients with severe CDAD had significantly shorter median survival times and more adverse outcomes than patients with mild or moderate CDAD...
  43. pmc A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma
    Craig C Hofmeister
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 56:1043-9. 2015
    ..Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy. ..
  44. pmc Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
    Jerry Tran
    Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 18:1250-4. 2012
    ..This may be an important adjunctive therapy for a debilitating disease with limited treatment options...
  45. pmc Regulation of acute graft-versus-host disease by microRNA-155
    Parvathi Ranganathan
    Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, Ohio State University, 460 West 12th Ave, Columbus, OH 43210, USA
    Blood 119:4786-97. 2012
    ..Altogether, our data indicate a role for miR-155 in the regulation of GVHD and point to miR-155 as a novel target for therapeutic intervention in this disease...
  46. pmc The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 173:96-104. 2016
    ..This trial is registered at clinicaltrials.gov (NCT00928018). ..
  47. ncbi request reprint Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
    Steven M Devine
    Blood and Marrow Transplantation Program, Section of Hematology Oncology, University of Illinois College of Medicine, 840 South Wood Street, M C 787, Chicago, IL 60612, USA
    Blood 99:2255-8. 2002
    ..These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM...
  48. ncbi request reprint Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates
    Steven M Devine
    Section of Hematology Oncology, Department of Surgery, University of Illinois College of Medicine, Chicago, USA
    Blood 101:2999-3001. 2003
    ..These data suggest that MSCs initially distribute broadly following systemic infusion and later may participate in ongoing cellular turnover and replacement in a wide variety of tissues...
  49. pmc Graft-versus-host disease: why have we not made more progress?
    Samantha M Jaglowski
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Curr Opin Hematol 21:141-7. 2014
    ..This potentially fatal complication occurs in approximately 50% of allo-SCT recipients...